Wall Street analysts expect that Apollo Endosurgery, Inc. (NASDAQ:APEN) will report sales of $16.67 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Apollo Endosurgery’s earnings. The highest sales estimate is $16.99 million and the lowest is $16.34 million. Apollo Endosurgery posted sales of $15.39 million during the same quarter last year, which would indicate a positive year over year growth rate of 8.3%. The firm is expected to issue its next earnings results on Wednesday, March 14th.

On average, analysts expect that Apollo Endosurgery will report full year sales of $16.67 million for the current fiscal year, with estimates ranging from $64.64 million to $65.30 million. For the next fiscal year, analysts expect that the business will report sales of $68.30 million per share, with estimates ranging from $67.20 million to $69.39 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Apollo Endosurgery.

APEN has been the topic of several research reports. Northland Securities restated a “buy” rating on shares of Apollo Endosurgery in a research report on Friday, October 27th. Zacks Investment Research upgraded Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $9.44.

In related news, major shareholder Stonepine Capital, L.P. bought 5,287 shares of the stock in a transaction that occurred on Tuesday, December 26th. The stock was purchased at an average cost of $5.00 per share, with a total value of $26,435.00. Following the purchase, the insider now directly owns 2,555,151 shares of the company’s stock, valued at approximately $12,775,755. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Bret Schwartzhoff bought 9,500 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average cost of $4.24 per share, with a total value of $40,280.00. Following the completion of the purchase, the vice president now directly owns 15,631 shares in the company, valued at $66,275.44. The disclosure for this purchase can be found here. Insiders bought 245,378 shares of company stock valued at $1,169,179 over the last ninety days. Insiders own 74.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Stonepine Capital Management LLC purchased a new stake in shares of Apollo Endosurgery in the 3rd quarter valued at about $11,067,000. King Luther Capital Management Corp purchased a new stake in shares of Apollo Endosurgery in the 3rd quarter valued at about $2,567,000. Russell Investments Group Ltd. purchased a new stake in shares of Apollo Endosurgery in the 3rd quarter valued at about $1,288,000. Woodmont Investment Counsel LLC purchased a new stake in shares of Apollo Endosurgery in the 3rd quarter valued at about $220,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Apollo Endosurgery in the 3rd quarter valued at about $119,000. 23.67% of the stock is owned by institutional investors and hedge funds.

Apollo Endosurgery (NASDAQ:APEN) remained flat at $$5.60 during midday trading on Friday. 96,218 shares of the company traded hands, compared to its average volume of 110,897. Apollo Endosurgery has a 1 year low of $3.55 and a 1 year high of $21.88. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.54 and a quick ratio of 2.00.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/16-67-million-in-sales-expected-for-apollo-endosurgery-inc-apen-this-quarter/1788820.html.

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Get a free copy of the Zacks research report on Apollo Endosurgery (APEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.